3 days Ago
juvaida khatun Incyte ( NASDAQ: INCY ) closed ~4.5% higher Monday after releasing promising data at the European Medical Society for Medical Oncology on Saturday on Zynyz (retifanlimab) for anal cancer. The gain represented the biotech's largest daily one since July 9, when it closed up ~4.
4%. The ESMO data showed that the median PFS in the Zynyz + chemo group was 9.3 months compared to 7.
4 months in the chemo only arm. In a note, Guggenheim's Michael Schmidt said the Zynyz regimen would lead to a "robust uptake in a high unmet need population." He rates Incyte a buy with a $92 price target (~39% upside based on Sept.
16 close), just raised from $86. More on Incyte Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript Incyte Corporation 2024 Q2 - Results - Earnings Call Presentation Incyte Zynyz improves progression-free survival in anal cancer Incyte's Monjuvi meets primary endpoint in follicular lymphoma phase 3 trial.
